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Abstract: Placental growth factor (PlGF) is crucial during placental development in early pregnancy. Several studies in 
pregnancies with complications such as preeclampsia or small for gestational age neonates find that PlGF levels are 
significantly lower in the first trimester, which implies that the concentration of PlGF could be used as an early 
screening biomarker for these conditions. This study aimed to compare the performance of chemiluminescence 
immunoassay (CLIA) and enzyme-linked immunosorbent assay (ELISA) for the quantification of human PlGF in 
serum. This is a comparative study on 88 pregnant women in the first trimester subjected to measurement of PlGF in 
serum using two commercially available kits: Human PlGF Quantikine HS ELISA (R&D Systems) and PlGF CLIA 
(Snibe). The overall coefficient of correlation between the tests was 0.93. When the cut-off value of 40 pg/mL was 
applied, it dropped significantly to 0.50 towards the lower values, while remaining an excellent 0.91 in the group with 
higher concentrations of PlGF. While R&D Systems’s ELISA seems to have better sensitivity, it is not very convenient 
to use for a small number of samples. Snibe’s CLIA automated method is user-friendly, fast and powerful. Both tests 
show excellent performance when indicating risk-free pregnancies. 
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Placental growth factor (PlGF) is a member of the 
vascular endothelial growth factor (VEGF) family, 
with an important role in angiogenesis.
1
 The main 
source of PlGF is the placental trophoblast, and it has 
been shown that abundant expression of PlGF in the 
trophoblast is crucial for the trophoblastic invasion of 
maternal spiral arteries during placental development in 
early pregnancy.
2
 The concentrations of PlGF 
physiologically increase throughout pregnancy, with a 
peak in the third trimester (approximately week 30), 
after which they decrease as a sign of placental 
maturation1. Several studies have found that in 
pregnancies with complications such as preeclampsia 
or small for gestational age neonates, the PlGF levels 
are significantly lower in the first trimester, which 





 gestational week) could be used 
as screening biomarker for these conditions.
3-5
 The 
possibility of effective prediction of preeclampsia 
would have a substantial impact on the improvement of 
outcome by establishing intensive antenatal monitoring 
for the pregnant women recognized as high risk 
patients and by undertaking direct measures (low dose 
Aspirin) for the prevention of the  disease.
6
  
In order to develop a comprehensive algorithm which 
will be able to use the PlGF concentration for the 
discrimination between affected and unaffected 
pregnancies and as a predictor of pregnancy 
complications, reference ranges based on large scale 
data should be established by every laboratory.
7
 
Furthermore, the relative contribution of other 
associated conditions and/or habits, such as maternal 
age and smoking status, method of conception, parity, 
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should be taken into account and converted to multiples 
of medians (MoMs).
8-9
 These goals are beyond the 
scope of our study, and they are currently being 
analyzed and are in process of preparation (personal 
communication). 
Many different methods for the determination of the 
PlGF concentration in human plasma/serum have been 
already proposed and are available on the market.
10-13
 
The aim of our study was to evaluate two commercially 
available immunoassay methods, enzyme-linked 
immunosorbent assay (ELISA) and chemiluminescence 
immunoassay (CLIA), and to calculate the correlation 
between the results. 
 
 
MATERIAL AND METHODS 
This study is part of a larger research project, entitled 
“Screening for preeclampsia in the first trimester: 
Serum levels of PlGF as opposed to mother 
characteristics”, whose aim is to establish the national 





 of gestational age. This project 
lasted from July 2018 to December 2019, and it 
included more than 800 pregnant women. The material 
in this study comprised pregnant women who met the 





 weeks, crown rump length (CRL) 
45-84 mm and maternal age of at least 18 years. The 
exclusion criteria were as follows: fetal demise, 
congenital fetal anomalies, serious mental illness of the 
woman, communication difficulties. At the starting 
point of the study, all women were questioned about 
their medical history and signed an informed consent at 
the Special Hospital for Obstetrics and Gynecology 
“Mother Teresa” in Skopje, Republic of North 
Macedonia. Data were collected following the NICE 
(National Institute for Health and Care Excellence) 
protocol for screening of preeclampsia, and venous 
blood was drawn. Six milliliters of venous blood were 
drawn in plain vacutainer (no anticoagulant). After 30 
min. at room temperature, the tubes were centrifuged 
for 10 minutes at 1500 rpm, the serum was transferred 
into 2 fresh tubes and stored at -20⁰C until analysis of 
the PlGF concentration, but for no more than 3 months. 
Measuring of the concentration was performed at the 
Institute for Immunobiology and Human Genetics at 
the Medical Faculty in Skopje. The specimens were 
transported to the Institute frozen in accordance with 
the cold chain rule. For quantitative analysis of PlGF, 
two commercially available kits were used: Human 
PlGF Quantikine HS ELISA kit from R&D Systems, 
(Minneapolis, Minnesota, United States) and PlGF 
CLIA kit from Snibe (Shenzhen, China).  
For comparison, sera from 88 pregnant women, most of 
them (68) selected on the basis of the data collected 
from the NICE protocol for screening of preeclampsia, 
and 20 randomly selected, were subjected to 
measurement using both methods, according to the 
manufacturer’s instructions, briefly explained below. 
Human PlGF Quantikine HS ELISA (R&D)® 
This manually performed immunoassay employs the 
quantitative sandwich immunoassay technique. A 
monoclonal antibody specific for human PlGF has been 
pre-coated onto a microplate. In the first step, 100 µL 
of RD1-22 diluent (a buffered protein base) is added to 
all wells. In the second step, 100 μL of standards and 
samples are then pipetted into the wells and left for 
incubation 1 hour at room temperature. Following a 
wash step, 200 µl of PlGF HS conjugate (horseradish 
peroxidase labeled) is added to all wells, and the plate 
is incubated 1 hour at room temperature. Another step 
of washing follows and then 50 µl of substrate solution 
is added to the wells, and the plate is left for an 
incubation of 1 hour at room temperature protected 
from light. In the next step, 50 µl of amplifier solution 
is added to the wells, and the plate is incubated for 30 
minutes at room temperature. The color development is 
stopped with 50 µl Stop solution to each well. 
Absorbance was measured at 490 nm using Wallac 
1420 Victor 2 ELISA plate reader from Perkin Elmer 
(Waltham, Massachusetts, United States). The 
concentrations of the measured samples were 
calculated using a standard curve that was obtained 
using dilution series (3.13, 6.25, 12.5, 25, 50, 100 and 
200 pg/mL) from a standard sample with defined 
concentration of 2000 pg/mL. 
 
 
PlGF CLIA (Snibe)® 
This automated immunoassay is performed on 
MAGLUMI 1000 fully automated chemiluminescence 
immunoassay analyzer from Snibe (Shenzhen, China). 
In the first step, 50 µl of sample (or calibrator/ control), 
ABEI labeled with anti-PlGF polyclonal antibody and 
magnetic microbeads coated with anti PlGF polyclonal 
antibody are mixed thoroughly and incubated at 37ºC, 
forming sandwich complexes. After precipitation in a 
magnetic field, the supernatant is decanted, and a 
washing cycle is performed. Subsequently, Starter 1+2 
are added to initiate a flash chemiluminescence 
reaction. The light signal is measured by a 
photomultiplier within 3 seconds as relative light units 
(RLUs) which are proportional to the concentration of 
PlGF present in the sample (or calibrator/ control). The 
serum PlGF levels are determined using previously 
generated 2-point calibration curve and a master curve 
(10 calibrations) provided by the manufacturer of the 
kit. 
The main characteristics of both assays used are 
summarized in Table 1. 
 
 
RESULTS AND DISCUSSION 
The mean PlGF concertation for the 88 analyzed 
samples using ELISA was 43.67 pg/mL, and using 
CLIA it was 46.45 pg/mL. When compared, the overall 
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Table 1. Assay characteristics 
Assay characteristics ELISA (R&D) CLIA (SNIBE) 
Assay platform Manual Automated 
Minimum sample 
required 
100 µL 50 µL 
Time to results ~4 h ~1.5 h 




Number of controls 




coefficient of correlation between the tests was 0.93, 
indicating very strong concordance. Keeping in mind 
the relevance of the PlGF concentration for the 
prediction of the pregnancy outcome, we further 
subdivided the results in two groups according to the 
first obtained results using the ELISA kit. Several 
studies analyzing the potential use of PlGF 
concentration as an early screening biochemical marker 
used in the first trimester of the pregnancy for 
predicting later preeclampsia or small for gestational 
age fetus have used cut-off value of 40 pg/mL. 
Accordingly, we have subdivided the results into two 
subgroups, the low concentration group (<40 pg/mL) – 
indicative of pregnancy complications, and the high 
concentration group (>40 pg/mL) – not likely to be 
associated with preeclampsia or small for gestation age 




Figure 1. Distribution of PlGF concentrations in two groups, low 
and high  
 
 
In the first group of samples with low concentrations of 
PlGF (<40 pg/mL), a total of 63 samples were detected 
in the ELISA measurement, and 55 in the CLIA 
measurement, while the coefficient of correlation for 
this group of results was 0.50. The coefficient of 
correlation between the groups with high 
concentrations was an excellent 0.91, calculated on 25 
results obtained using ELISA and 33 samples analyzed 
with the CLIA method. 
Despite the excellent correlation between overall 
results, it is worth noting that this correlation 
significantly dropped towards the lower values of PlGF 
(Table 2). 
Based on simple observation, one could notice that the 
results for PlGF concentration obtained with the two 
methods are perfectly concordant towards higher 
concentrations and would most efficiently rule-out the 
pregnancies in which no complications are to be 
expected. On the other hand, the two methods perform 
more differently when measuring lower concentrations 
of PlGF in serum, and, while still keeping the 
coefficient of correlation of 0.5 within the limits of 
moderate correlation, it is significantly lower than 
when analyzed on entire cohort and again on samples 
with concentration above 40 pg/mL. 
 
 
Table 2. Median value and coefficient of correlation according to 
two subgroups of results, low and high 
Group of 
results 
Assay* N M CC 
Low (<40 pg/mL) 
R&D 63 26.2 
0.50 
Snibe 55 29.51 
High (>40 pg/mL) 
R&D 25 57.72 
0.91 







Legend: * - assay manufacturer; N - number of results; M - median; 
CC - coefficient of correlation 
 
 
However, without any intention to neglect authors 
advocating taking into account all the important 
associated characteristics and their conversion to 
Multiples of Medians, by simply counting the analyzed 
pregnancies, we might conclude that by simply 
applying the cutoff value of 40 pg/mL on our cohort of 
88 analyzed samples, we would be able to recognize 15 
out of 19 pregnancies actually associated with high 
risk. Within these 15 positively selected patients, likely 
to develop pregnancy complications, 3 are detected 
only when using ELISA, while one patient stratified in 
the non-risk group according to the ELISA result was 
correctly detected with the CLIA method (Figure 2). 
Our study has its limitations. Some of them are the size 
of the cohort, the heterogeneity of the patients and 
different ages within the studied group. Including as 
many samples as possible for parallel analysis with 
both methods will produce much more objective 
insights. We are certain that the ongoing inclusion and 
conversion of all contributing factors into MoMs will 
greatly improve the delineation capacity and will add 
power to discriminate between both immunoassays. 
However, this is influenced by limited funds. In the 
meanwhile, we were able to conclude that both tests 
have their strengths and weaknesses. For example, 
when taking into consideration of the outcome of the 
pregnancy,  ELISA  seems  to   have  better   sensitivity  
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Figure 2. High concentration of PlGF (>40 pg/mL) as measured by R&D 
 
 
since it detects truly high-risk pregnancies more 
efficiently. On the other hand, it is not very convenient 
for a small number of samples. Inclusion of calibrators 
and negative controls in every single run greatly 
increases the price per test. Higher level of lab 
experience is critical for yielding quality results. The 
CLIA automated method is very user-friendly; almost 
no experience on the part of the lab technician is 
needed. The technique is fast and powerful, and results 
are obtained within 90 minutes. Its sensitivity was a bit 
lower than the ELISA method, having measured as 
normal a few samples from women as finished their 
pregnancies with preeclampsia. But again, a better 
evaluation on a larger cohort is needed for a definitive 
conclusion. Both tests show excellent performance 
when indicating risk-free pregnancies, while more 
attention and possibly repetitive measurements could 
help in identifying pregnancies at risk solely based on 
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